EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY-NC 4.0

Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer

Jonathon Carll iD, Weiwei Shi iD, Marlon Perera iD, Nathan Lawrentschuk iD, Thilakavathi Chengodu, Dixon Woon

BJU International · 2025-11 · 136 (5) · 800-804

DOI: 10.1111/bju.16872 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BJU International, online erschienen am 24.07.2025. Verfasst von Jonathon Carll und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Positron-Emission Tomography, Practice Guidelines as Topic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To provide a comprehensive review and analysis of guidelines from various professional and medical organisations regarding the use of prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) as a staging scan for men with newly diagnosed intermediate‐risk prostate cancer (PCa). Materials and Methods English‐language guidelines and recommendations from the following associations and societies were reviewed and critically analysed: European Association of Urology (EAU), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), Canadian Urological Association (CUA), American Society for Clinical Oncology (ASCO), Society for Nuclear Medicine and Medical Imaging (SNMMI).

Results

There is significant disagreement among guidelines regarding whether PSMA PET is a useful staging tool for men with a new diagnosis of intermediate‐risk PCa. There is a stronger consensus that PSMA PET is useful in staging high‐risk PCa.

Conclusion

Whilst there is a growing body of evidence that supports the use of PSMA PET in newly diagnosed PCa, there is significant disagreement regarding its use for men with intermediate‐risk disease. Recommendations are generally weak and based on expert opinions. This is an area of considerable ongoing research, and guidelines are likely to change as new evidence emerges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceGlutamate Carboxypeptidase IIPositron-Emission TomographyPractice Guidelines as TopicProstatic NeoplasmsHumansMaleNeoplasm Staging

Stichwörter der Autor:innen

GuidelinesIntermediate‐RiskPSMA PETProstate CancerStaging

Substanzen

Antigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Urology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Victoria, Australia.
  • Epworth Healthcare, Melbourne, Victoria, Australia.
  • Department of Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Department of Surgery, Austin Healthcare, Heidelberg, Victoria, Australia.

ORCID-Profile: Jonathon Carll, Weiwei Shi, Marlon Perera, Nathan Lawrentschuk

Zitieren

APA

Carll, J., Shi, W., Perera, M., Lawrentschuk, N., Chengodu, T., & Woon, D. (2025). Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer. BJU International, 136(5), 800-804. https://doi.org/10.1111/bju.16872

Vancouver

Carll J, Shi W, Perera M, Lawrentschuk N, Chengodu T, Woon D. Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer. BJU International. 2025;136(5):800-804. doi:10.1111/bju.16872

BibTeX
@article{Carll2025,
  author = {Carll, Jonathon and Shi, Weiwei and Perera, Marlon and Lawrentschuk, Nathan and Chengodu, Thilakavathi and Woon, Dixon},
  title = {Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate‐risk prostate cancer},
  journal = {BJU International},
  year = {2025},
  volume = {136},
  number = {5},
  pages = {800--804},
  doi = {10.1111/bju.16872}
}
Kostenlos starten →